Audio Conferences
Molecular Diagnostics for Community Hospital Labs:
|
|
|
|
How the implementation of molecular diagnostics can have a positive impact on patient care and financial growth |
| Molecular diagnostics are transforming the way your lab tests for infectious diseases and solid tumors. Increasingly, molecular tests supplement and often replace conventional diagnostic assays. They’re also being used to obtain prognostic data, and in some cases dictate therapy.Molecular-based infectious disease assays enhance client/physician satisfaction by providing diagnostic information that yield quick results, making clinical decisions much easier. As a result, clinicians are increasingly asking for these tests.
|
|
Why Health Insurers Want to Pre-Authorize Genetic Assays and Expensive Clinical Pathology Lab Tests |
|
 Matt Zubiller |
Learn how and why your laboratory must be prepared to ensure “the right test, at the right cost and the right time.” |
|
Pre-authorization of genetic tests and molecular assays is a fast-growing trend. This is a serious threat to clinical labs, hospital outreach programs, and pathology groups—just the newest genetic tests give laboratories a way to deliver more diagnostic value to physicians. Join us on this upcoming audio conference to get the information you need about these powerful developments—along with how you can position your laboratory to be a preferred provider to health plans and physicians in your community.
|
|
How to Protect Your Laboratory’s Most Important Business Assets from Internal and External Threats |
|
 James Giszczak |
Critical new developments affecting trade secrets, non-compete agreements and employee handbooks |
| Every pathology practice and clinical laboratory has key assets that drive the value of the business. The importance of these assets is reflected in contracts and agreements on trade secrets, in non-compete covenants with executives and sales reps, and in employee handbooks. These are all designed to protect and maximize the value of the group practice or lab on behalf of its partners and owners.
|
|
Transfusion & Blood Management:
|
|
 Timothy Hannon, MD |
Tips and strategies that helped one hospital reduce blood costs by $3.5 million in just three years. |
|
Blood acquisition costs have more than doubled in the past few years and will continue to rise as blood production costs increase and the supply struggles to meet the demand. But that’s just the tip of the iceberg. Factor in other costs, like labor, supplies and blood administration, to name a few, and the price tag for transfusing patients exceeds blood-acquisition costs by five times or more.
|
|
How to Negotiate Part A Pathology Reimbursements
|
|
Win-win breakthrough aligns hospitals and pathologists in Pathology Part A Agreements that deliver added value! |
|
|
Hospitals are always looking for ways to cut costs. And because pathologists are hospital-based, they’re an easy target, especially in tough times like these. Typically, the amount of pathologists’ Part A reimbursement depended almost exclusively on your skills as a negotiator. But these days, that’s no longer enough. With the approval of the new healthcare reform legislation, all costs will be under increased scrutiny. As a result, one thing is almost certain: pathologists are going to have a difficult time increasing-or even maintaining-their Part A reimbursement levels come contract renewal time.
|
|
Managed Care’s Most Significant New Trends in 2010
|
|
 Sam Merkouriou |
Pre-authorization of molecular tests
|
| Managed-care companies are about to target expensive molecular and genetic tests by requiring pre-authorization and patient counseling. In addition, regional and national health insurers now require that all network laboratories provide them with clinical data and utilization reports on these tests. These requirements are the latest trends to hit managed-care contracting, and pose a direct threat to every clinical laboratory and pathology group-including yours.
|
|
The A-to-Z of Vitamin D: Why It’s Today’s Hottest Lab Test! |
|
 Bruce Hollis, PhD |
How Labs can deliver maximum clinical and financial value
|
| You’ll get the latest information on the vigorous debate going on about what level of Vitamin D should be used by clinicians to determine a patient’s sufficiency. Find out how the healthcare establishment picked an RDA number that-as clinical knowledge advances-is much too low to support optimum health. And how new clinical studies are providing persuasive evidence that the daily intake of Vitamin D should be closer to 5,000 units per day.Understanding the changing science behind Vitamin D and why it is the fast-growing assay, by volume, on your lab’s test menu is critical to the future success of your lab.
|
|
Next Page
